3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
95
Carcinoma, Non-Small-Cell Lung
87
Lung Neoplasms
21
Squamous Cell Carcinoma of Head and Neck
19
Melanoma
19
Triple Negative Breast Neoplasms
14
Stomach Neoplasms
13
Breast Neoplasms
13
Neoplasm Metastasis
11
Head and Neck Neoplasms
11
Carcinoma, Renal Cell
11
Endometrial Neoplasms
10
Urinary Bladder Neoplasms
9
Neoplasms
9
Carcinoma
9
Carcinoma, Transitional Cell
7
Carcinoma, Hepatocellular
7
Colorectal Neoplasms
6
Uterine Cervical Neoplasms
4
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Neoplasms by Site
4
Esophageal Neoplasms
4
Cholangiocarcinoma
4
Thoracic Neoplasms
3
Small Cell Lung Carcinoma
3
Skin Neoplasms
3
Respiratory Tract Neoplasms
3
Respiratory Tract Diseases
3
Lung Diseases
3
Interventions
padeliporfin
3
pembrolizumab
1
palladium-bacteriopheophorbide
1
enfortumab vedotin
1
Radiation Dose Hypofractionation
1
Mitomycin
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Male Urogenital Diseases
×
pembrolizumab
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled